Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.

Studied

Randomized withdrawal trial comparing continued tirzepatide with switching to placebo after initial tirzepatide treatment.

Who / model

670 adults with obesity or overweight without diabetes completed 36 weeks of initial treatment, then entered a further 52-week randomized comparison.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

After initial average weight loss of 20.9%, weight fell another 5.5% with continued tirzepatide but rose 14.0% after switching to placebo. For the key secondary outcome, 89.5% versus 16.6% maintained at least 80% of their initial weight loss. Digestive adverse events were more common with continued tirzepatide.

Limits

The randomized comparison included people who had completed the initial tirzepatide treatment period.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary